Research Trends

  Gynecologic cancer is any cancer that influences a lady's regenerative organs like cervical, ovarian, uterine, vaginal, and vulvar. It is one of the main sources of death among ladies. As indicated by the American Cancer Society, around 13,800 new instances of intrusive cervical cancer are required to be analyzed in the U.S. in 2020 and the sickness is relied upon to prompt passing of 4,290 ladies around the same time. Avastin (Bevacizumab), Bevacizumab, Bleomycin Sulfate, Hycamtin (Topotecan Hydrochloride), Keytruda (Pembrolizumab), Mvasi (Bevacizumab), Pembrolizumab, and Topotecan Hydrochloride are a portion of the generally utilized gynecological cancer drugs. Bevacizumab, sold under the brand name is utilized for the therapy of colorectal, lung, glioblastoma, kidney, cervical, and ovarian cancer. It is affirmed to treat metastatic colorectal cancer (mCRC) for first-or second-line therapy in blend with intravenous fluorouracil–based chemotherapy. Bevacizumab, one more of t

  Gynecologic cancer is any cancer that affects a woman's reproductive organs such as cervical, ovarian, uterine, vaginal, and vulvar. It is one of the leading causes of death among women. According to the American Cancer Society, about 13,800 new cases of invasive cervical cancer are expected to be diagnosed in the U.S. in 2020 and the disease is expected to lead to death of 4,290 women in the same year. Avastin (Bevacizumab), Bevacizumab, Bleomycin Sulfate, Hycamtin (Topotecan Hydrochloride), Keytruda (Pembrolizumab), Mvasi (Bevacizumab), Pembrolizumab, and Topotecan Hydrochloride are some of the widely used gynecological cancer drugs. Bevacizumab, sold under the brand name is used for the treatment of colorectal, lung, glioblastoma, kidney, cervical, and ovarian cancer. It is approved to treat metastatic colorectal cancer (mCRC) for first- or second-line treatment in combination with intravenous fluorouracil–based chemotherapy. Bevacizumab, another of the gynecological ca